Premium
Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against s‐100 subunits
Author(s) -
Cho Kwang Hyun,
Hashimoto Ken,
Taniguchi Yoshiki,
Pietruk Teresa,
Zarbo Richard J.,
An Teisa
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19900815)66:4<765::aid-cncr2820660428>3.0.co;2-m
Subject(s) - lentigo maligna , monoclonal antibody , nevus , melanoma , pathology , immunohistochemistry , monoclonal , hmb 45 , medicine , superficial spreading melanoma , dysplastic nevus , antibody , cancer research , immunology
Immunohistochemical localization of S‐100 protein α and β subunits in the cells of melanocytic nevi and malignant melanomas was studied by using monoclonal antibodies directed against each subunit. Although polyclonal anti‐S‐100 reactivities have been demonstrated uniformly in all nevus cells and melanoma cells, monoclonal anti‐S‐100α and anti‐S‐100β reactivities were either absent or rarely found in ordinary junctional nevi or junctional nests of ordinary compound nevi. However, in the junctional nests of dysplastic junctional nevi and junctional components of dysplastic compound nevi, monoclonal anti‐S‐100α reactivity become more frequent, whereas monoclonal anti‐S‐100β reactivity remains negative. In the superficial variety of melanomas such as superficial spreading melanoma and lentigo maligna melanoma, monoclonal anti‐S‐100β is nonreactive until vertical growth or invasiveness begins. Most nodular melanomas are positively stained with both monoclonal anti‐S‐100α and anti‐S‐100β. It is suggested that monoclonal anti‐S‐100α can be an indicator of active junctional nevus of melanocytic nevi and the reactivity with monoclonal anti‐S‐100β may be related to vertical progression of superficial spreading melanomas and lentigo maligna melanomas.